Pfiz­er sweeps out a line­up of neu­ro­science drugs — as well as can­cer and NASH pro­grams — in­to the scrap heap

Any­one shop­ping for some ear­ly- and mid-stage neu­ro­sciences pro­grams should look over the menu of dis­con­tin­ued pro­grams out from Pfiz­er $PFE this morn­ing.

As the phar­ma gi­ant al­ready not­ed, it is get­ting rid of every­thing on the neu­ro­sciences side ex­cept its late-stage pain pro­gram al­lied with Eli Lil­ly. So the chop­ping block to­day in­cludes a Phase I gam­ma se­cretes ap­proach, PF-06648671, as well as a GA­BA-A re­cep­tor ag­o­nist for epilep­sy and a dopamine 1 ac­ti­va­tor for cog­ni­tive dis­or­ders.

To read Endpoints News become a free subscriber

Unlock this article instantly, along with access to limited free monthly articles and our suite of newsletters

SIGN UP LOG IN